Table 1. Main characteristics of studies exploring the relationship between L1CAM expression and tumor prognosis.
| Author | Year | Country | Cancer type | Stage/grade | No. of patients | Age Median(range) | Follow-up time Median(range) | Detection method | Cut-off | Outcomes |
|---|---|---|---|---|---|---|---|---|---|---|
| Allory | 2005 | France | Renal cell cancer | pT1-pT4 | 103 | NA | 34.7m(2-133) | IHC(mAb272) | >10 % | DFS |
| Kaifi | 2006 | Germany | GIST | NA | 55 | 56.35y | 41m | IHC(UJ127) | ≥10% | RFS |
| Boo | 2007 | Korea | Colorectal cancer | I-IV | 138 | 57.9y(18-82) | 70.9m(3-129) | IHC(UJ127) | >5% | OS |
| Kaifi | 2007 | Germany | Colorectal cancer | pT1-pT4 | 247 | 65y | 46m | IHC(UJ127) | score>1 | DSS,OS |
| Wachowiak | 2007 | Germany | Neuroblastoma | Grade 1-3 | 66 | 30m | 72m | IHC(UJ127) | NA | DFS,OS |
| Daponte | 2008 | Greece | Ovarian cancer | Grade 1-3 | 95 | NA | 3y | IHC(UJ127) | score>1 | PFS |
| Zecchini | 2008 | Italy | Ovarian cancer | I-IV | 211 | NA | 3.9y(0.14-11.47) | IHC(NA) | Membrane(+) | DFS,OS |
| KATO | 2009 | Japan | Colorectal cancer | I-IV | 71 | NA | 34m(1-67) | IHC(UJ127) | score>2 | OS |
| Kim | 2009 | Korea | Neuroendocrine tumor | I-IIIB | 55 | 64y(24-80) | 52m(2.6-133.7) | IHC(A10-A3) | >5% | DFS,OS |
| Kodera | 2009 | Japan | Gastric cancer | pT3 | 72 | 59.5y | 6.11y(5-9.01) | IHC(UJ127) | ≥10% | OS |
| Schroder | 2009 | Germany | Breast cancer | pT1-pT4 | 167 | 55.5y(29-85) | 84m(8-169) | DNA-microarray | ≥200 | DFS,OS |
| Li | 2009 | Korea | cholangiocarcinoma | I-IV | 75 | 65y(48-84) | 16m(1-94) | IHC(A10-A3) | scores=+2/+3 | PFS,OS |
| Ben | 2010 | China | PDAC | pT1-pT3 | 94 | 59y(31-79) | 20m(3-45) | IHC(UJ127) | score≥30 | OS |
| BERGMANN | 2010 | Germany | PDAC | pT3-pT4 | 110 | 63.2y(37-88) | 20m(2-64) | IHC(14.10) | ≥20% | OS |
| FANG | 2010 | China | Colorectal Cancer | Dukes A-D | 142 | 55y(15-78) | >5y | IHC(UJ127) | >30% | OS |
| Huszar | 2010 | Germany | Endometrial cancer | IA-IIB | 272 | 66.6y(32.7-87.7) | NA | IHC(14.10) | scores≥1 | RFS |
| Tsutsumi | 2011 | Japan | PDAC | Grade 1-3 | 107 | 66y(37-80) | 15.8m | IHC(UJ127) | ≥10% | OS |
| Choi | 2011 | Korea | Gallbladder cancer | I-IV | 69 | 67y(35-87) | 37m(1-117) | IHC(A10-A3) | >5% | DFS,OS |
| Doberstein | 2011 | Germany | Renal cell cancer | pT1-pT3 | 282 | 63y(29-88) | 40m(1-140) | IHC(14.10) | ≥5% | OS |
| Tischler | 2011 | Switzerland | Non-small cell lung cancer | pT1-pT4 | 472 | NA | 25m(0-169,PFS); 51m(1-169,OS) | IHC(14.10) | scores≥1 | PFS,OS |
| Zander | 2011 | Germany | GIST | NA | 65 | 61y(28-81) | 37m(0-273) | ELISA | >2 ng/ml | RFS |
| Bondong | 2012 | Germany | Ovarian cancer | IIA-IV | 232 | 57y(18-85) | 31m | ELISA | 5.4ng/ul | PFS,OS |
| Guo | 2012 | China | Hepatocellular cancer | I-IV | 130 | NA | 8.6y | IHC(UJ127) | scores≥4 | DFS,OS |
| Chen | 2013 | China | Gastric cancer | I-IV | 156 | NA | 30m(3-112) | IHC(5G3) | scores≥1 | OS |
| ZHANG | 2013 | China | Breast cancer | Grade 1-3 | 97 | 53y(28-87) | 51m(3-101) | IHC(14.10) | scores≥30 | OS |
| Zeimet | 2013 | Austria | Endometrial cancer | IA-IB | 1021 | 64y(34-96) | 5.3y | IHC(14.10) | >10 % | DFS,OS |
| Bosse | 2014 | Netherlands | Endometrial cancer | IB-IIA | 865 | 68.1y(41-90) | NA | IHC(14.10) | >10 % | OS |
| Doberstein | 2014 | Germany | Breast cancer | pT1-pT4 | 52 | 58.7y(33-84) | 67.4m | IHC(14.10) | >10 % | DFS,OS |
| Ito | 2014 | Japan | Gastric cancer | I-IV | 112 | NA | NA | RT-PCR | NA | DFS,OS |
| Van | 2016 | Netherlands | Endometrial cancer | I-IV | 116 | 66.3y(21-85) | 28.6m(0.3-120) | IHC(14.10) | >10 % | RFS |
| Smogeli | 2016 | Norway | Endometrial cancer | IA-IB | 388 | NA | 4.8y(0.1-8.8) | IHC(14.10) | >10 % | RFS,OS |
| Abdel | 2016 | Austria | Ovarian cancer | I-IV | 138 | 62.8y | 44m(1-242) | RT-PCR | >0.23 | PFS,OS |
| Dellinger | 2016 | USA | Endometrial cancer | I-IV | 545 | 64y(31-90) | 23m(0-192) | RNA-seq | >5.37 fold | OS |
| Geels | 2016 | Netherlands | Endometrial cancer | I-IV | 103 | 63y(24-86) | 57m(0-148) | IHC(14.10) | >10 % | DSS,PFS |
| Notaro | 2016 | Austria | Endometrial cancer | I-IV | 82 | NA | 11.6y(0.17-21.88) | RT-PCR | >10% | DFS,OS |
| Trietsch | 2016 | Netherlands | Vulvar cancer | I-IV | 348 | 71y | 4y | IHC(14.10) | ≥5% | DSS,OS |
| Van | 2016 | Multiple | Endometrial cancer | I-IV | 1199 | 64y(31-93) | 62m(0-229) | IHC(14.10) | >10 % | DFS,OS |
Abbreviations: GIST, gastrointestinal stromal tumors; PDAC, pancreatic ductal adenocarcinoma; NA, not available; IHC, immunohistochemistry; OS, overall survival; DFS, disease-free survival; DSS, disease-specific survival; RFS, recurrence-free survival; PFS, progression-free survival;